Bao‐Vi C. Tran, Anna Zenno, Nazrat Mirza, Evan P. Nadler, Sheila M. Brady, Otiti A. Mayo, Alexa Lyman, Stephanie T. Chung, Kong Y. Chen, Peter Walter, Hongyi Cai, Shanna Yang, Sara A. Turner, Jack A. Yanovski, Bobby K. Cheon
BACKGROUND: In adolescents with obesity ≥ 1-year post-vertical sleeve gastrectomy (VSG), a pilot trial of liraglutide demonstrated a 4.3% BMI reduction. This secondary analysis evaluated energy intake changes (∆EI) and associations of ∆EI with oral glucose tolerance test (OGTT) outcomes and end-of-trial liraglutide plasma concentrations. METHODS: At baseline and after 4 months of liraglutide, participants completed a standardised buffet meal following a 2-h OGTT. Liraglutide plasma area under the curves (AUCs) were quantified using LC-MS/MS. RESULTS: ) completed buffet meals at both visits. Mean energy intake decreased by 161.7 ± 264.3 kcal (p = 0.04) and food mass by 72.5 ± 123.4 g (p = 0.02), with proportional reductions in absolute macronutrient intake but no change in macronutrient distribution. Neither Liraglutide AUC (n = 17) nor OGTT outcomes were significantly associated with ∆EI or changes in body weight. CONCLUSIONS: In adolescents post-VSG treated with liraglutide, overall food intake decreased without significant changes in macronutrient composition.